Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | CD19-directed CAR-T in patients with R/R high-grade lymphoma

Claire Roddie, MD, PhD, University College London Hospitals NHS Foundation Trust, London, UK, gives an overview of the findings of a study which investigated the outcomes of patients with relapsed/refractory (R/R) high-grade lymphoma, deemed unfit for autologous stem cell transplantation (ASCT), who receive CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study analyzed data from 400 patients with R/R high-grade lymphoma who were approved for treatment with axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) between December 2018 and November 2020 across 10 UK centers. Dr Roddie reports that 20% of patients approved for CAR-T therapy were deemed unfit for ASCT, of which 65% underwent infusion. Dr Roddie discusses the study’s finding and comments on implications for clinical practice and patient selection for CAR-T therapy. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.